Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BL-M05D1 |
| Synonyms | |
| Therapy Description |
BL-M05D1 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CLDN18.2 linked to the topoisomerase I inhibitor Ed-04, which potentially inhibits growth of tumors expressing CLDN18.2 (Cancer Res (2024) 84 (6_Supplement): 3140). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BL-M05D1 | BLM05D1|BL M05D1 | CLDN18.2 Antibody 23 | BL-M05D1 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CLDN18.2 linked to the topoisomerase I inhibitor Ed-04, which potentially inhibits growth of tumors expressing CLDN18.2 (Cancer Res (2024) 84 (6_Supplement): 3140). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07021066 | Phase I | BL-M05D1 | Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors | Recruiting | USA | 0 |